BriaCell Therapeutics Corp. financial data

Symbol
BCTX, BCTXW, BCTXZ on Nasdaq
Location
West Vancouver, British Columbia, Canada
Fiscal year end
31 July
Latest financial report
10-K - Q2 2025 - 16 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 270 % +31.9%
Return On Equity -291 % -323%
Return On Assets -180 % -303%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.88M shares -94.8%
Common Stock, Shares, Outstanding 1.88M shares +1445%
Entity Public Float 94.5M USD +48.3%
Common Stock, Value, Issued 102M USD +41%
Weighted Average Number of Shares Outstanding, Basic 423K shares +286%
Weighted Average Number of Shares Outstanding, Diluted 423K shares +286%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.3M USD -21.7%
General and Administrative Expense 5.93M USD -3.55%
Operating Income (Loss) -27.2M USD +18.4%
Nonoperating Income (Expense) 115K USD -56.4%
Net Income (Loss) Attributable to Parent -26.3M USD -449%
Earnings Per Share, Basic -62 USD/shares -42.4%
Earnings Per Share, Diluted -62 USD/shares -42.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.5M USD +1117%
Accounts Receivable, after Allowance for Credit Loss, Current 15.2K USD +2.26%
Assets, Current 19.9M USD +445%
Property, Plant and Equipment, Net 297K USD -23.5%
Intangible Assets, Net (Excluding Goodwill) 185K USD -7.64%
Assets 21.6M USD +269%
Liabilities, Current 3.98M USD -46.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -139K USD 0%
Retained Earnings (Accumulated Deficit) -112M USD -30.8%
Stockholders' Equity Attributable to Parent -3.78M USD -137%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 17.3M USD
Liabilities and Equity 21.6M USD +269%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.96M USD +8.55%
Net Cash Provided by (Used in) Financing Activities 12M USD
Net Cash Provided by (Used in) Investing Activities -75K USD
Common Stock, Shares, Issued 1.88M shares +1445%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.93M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.5M USD +1117%
Deferred Tax Assets, Valuation Allowance 24.3M USD +34.9%
Deferred Tax Assets, Gross 28.4M USD +29.6%
Depreciation 22.8K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.9M USD +51.1%
Property, Plant and Equipment, Gross 457K USD
Deferred Tax Assets, Operating Loss Carryforwards 8.49M USD +53.2%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 7.92M USD
Deferred Tax Assets, Net of Valuation Allowance 4.1M USD +4.9%
Share-based Payment Arrangement, Expense 392K USD +39.5%